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Abstract Cellular senescence has recently been
established as a key driver of organismal ageing.
The state of senescence is controlled by extensive
rewiring of signalling pathways, at the heart of which
lies the mammalian Target of Rapamycin Complex I
(mTORC1). Here we discuss recent publications
aiming to establish the mechanisms by which
mTORC1 drives the senescence program. In particu-
lar, we highlight our data indicating that mTORC1 can
be used as a target for senescence cell elimination
in vitro. Suppression of mTORC1 is known to extend
lifespan of yeast, worms, flies and somemouse models
and our proof-of-concept experiments suggest that it
can also act by reducing senescent cell load in vivo.
Keywords mTOR  Senescence  DNA damage 
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Introduction
Cellular senescence is a potent tumour suppressor
mechanism that also plays an important role in wound
healing and development. There is evidence, particu-
larly in mouse models that it can however turn from
protector to antagonist with increasing age when these
metabolically active cells accumulate in tissues (de
Magalhaes and Passos 2018). Replicative exhaustion,
DNA damage, excessive stress and oncogene activa-
tion can all activate the senescence program, resulting
in an irreversible exit from the cell cycle. Senescence
is characterised by an increase in cell size, increased
organelle content and a robust senescence-associated
secretory phenotype (SASP). The accumulation of
senescent cells within a number of tissues including
lung (Birch et al. 2015), muscle (Sousa-Victor et al.
2014), liver (Ogrodnik et al. 2017) and bone (Farr et al.
2017) is associated with reduced tissue regeneration
capacity, function and integrity. Moreover the inflam-
matory environment mediated by SASP has been
intimately linked with driving gross tissue changes
such as fibrosis (Schafer et al. 2018) and increased risk
of cellular transformation via the so-called bystander
effect (Schosserer et al. 2017; Rao and Jackson 2016).
Seminal work from theMayo Clinic demonstrated that
Olena Kucheryavenko and Glyn Nelson have contributed
equally to this work.
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clearance of p16/Ink4a positive cells (a marker of
senescence) can improve age-related pathologies and
lengthen healthy lifespan in wild-type and progeroid
mice (Baker et al. 2011; Baker et al. 2016). Others
have further demonstrated the health benefits of
removing senescent cells in mouse models, including
an improvement in post-trauma tissue regeneration
and alleviating chemotherapy-associated fatigue (Jeon
et al. 2017; Demaria et al. 2017). This latter report
further described that T cell p16/Ink4a expression in
humans correlates with severity of chemotherapy drug
toxicity indicating their clearance could be therapeu-
tically beneficial. Due to the economic, social and
medical burden of ageing in the Western world, the
need to find interventions to improve healthspan is
fundamentally important. Understanding more about
the mechanisms driving and maintaining senescence
and senescence-associated phenotypes may support
the identification of targeted, safe interventions to
meet this ultimate goal.
The central role of the mammalian target of
rapamycin complex 1 (mTORC1) in driving senes-
cence-associated phenotypes including SASP and
increased mitochondrial content has been comprehen-
sively established (Korolchuk et al. 2017; Lopez-Otin
et al. 2013; Correia-Melo. et al. 2018). Further to this,
we recently demonstrated that mTORC1 dependency
may represent a targetable vulnerability in senescent
cells that could be used to eliminate them (Carroll
et al. 2017). mTORC1 is a master regulator of cell
growth, the activity of which is tightly controlled by
the balance between mitogenic and stress signals.
Some of the most potent activators of mTORC1 are
growth factors and amino acids which work at least in
part to control the localisation and thus activation of
the mTORC1 complex on the lysosome/late endosome
surface. It is on the lysosomal surface that mTORC1
can ‘sense’ changes in amino acids and growth factors
via a huge number of regulatory proteins and
complexes including the Rag-Ragulator complexes
and Tuberous Sclerosis Complex (TSC) (Carroll and
Dunlop 2017; Wolfson and Sabatini 2017; Ben-Sahra
and Manning 2017). In its active form, mTORC1
drives protein translation, lipid and nucleotide syn-
thesis as well as inhibiting the catabolic process of
autophagy to support cell growth and metabolism.
During periods of limiting nutrient availability,
mTORC1 is switched off and autophagy activity
increases to sequester cytoplasmic material and
deliver it to the lysosomes for degradation. Liberation
of the resulting free amino acids, lipids and carbohy-
drates from the lysosome supports cell survival
(Carroll et al. 2015).
Senescent cells undergo dramatic rewiring of these
pro-growth and scavenging mechanisms that drive
their increased metabolism and survival (Carroll et al.
2017; Narita et al. 2011). In particular we recently
demonstrated that mTORC1 activity is resistant to
starvation of amino acids and growth factors in
senescence which prevents starvation-induced activa-
tion of autophagy (Carroll et al. 2017). Mechanisti-
cally, the basal expression of autophagy and lysosome
proteins is grossly elevated in senescence and this
may contribute to increased levels of intracellular
amino acids which activate mTORC1 and render it
insensitive to the availability of exogenous nutrients.
Thus senescence results in a unique re-equilibrium
between mTORC1 and autophagy (Carroll et al. 2017;
Carroll and Korolchuk 2018). We identified that this
can be targeted to kill senescent cells; treatment with
lysosome inhibitors or Torin1 in the absence of
exogenous nutrients selectively causes senescent cell
death in vitro (Carroll et al. 2017).
Methods
Animal procedures were performed according to
protocols approved by the Home Office (Personal
Licence 60/4542 (OK)) and animal health was mon-
itored according to FELASA guidelines. Male immun-
odeficient NSG mice were purchased from Charles
River UK breeding facility. Mice (13-17 weeks old)
were randomly assigned to groups at the commence-
ment of the treatment mice. Mice in both groups had
ad libitum access to standard chow and water. Mice
were injected intraperitoneally with a solution of
20 mg/kg Torin1 (Tocris) or vehicle every other day
for 7 days. Torin1 solution was prepared in 100%
N-methyl-2-pyrrolidone and diluted with sterile
PEG400 and water for injections at the ratio of 1:2:2
immediately prior to injection. Liver tissue was
harvested in 10% solution of paraformaldehyde
(PFA) and 24 h later were paraffin embedded. Three
independent animal experiments were quantified.
Paraffin sections (3 lm) were cut and subjected to
immunofluorescence and in situ hybridisation staining
as described previously (da Silva et al. 2019) using
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primary rabbit anti-cH2AX (CST #9718, 1:250) and
Cy3-labelled telomere specific (C3TA2)3 peptide
nucleic acid (PNA) probe (4 ng ll-1, Panagene) using
denaturation at 80 C and hybridization for 2 h at
room temperature in the dark. Confocal z stack images
were collected on an SP8 Confocal Microscope
(Leica) using a 63X Plan-Apo/1.4 NA Oil objective
at Nyquist sampling density. Images were analysed
with ImageJ software (https://imagej.nih.gov/ij/).
cH2A.X- and telomere overlap, and cH2A.X foci
were manually counted. A minimum of 100 nuclei
were counted per animal. Statistical analysis (T tests
between animal means) was performed with Sigma-
plot software (v 13, Systat Software Inc.).
Results and Discussion
Our proof-of-principle study demonstrates that target-
ing persistent mTORC1 in vivo reduced the number of
hepatocytes harbouring a key marker of senescence,
telomere-associated DNA damage foci (TAFs) as
measured by co-localisation of a telomere probe and
cH2AX (Fig. 1a–c) (Hewitt et al. 2012; Fumagalli
et al. 2012). Indeed, both the percentage of cells with
TAFs, and the percentage of cells with more than two
TAFs decreased after short term (7 day) administra-
tion of the mTORC1 inhibitor, Torin1, while the
overall number of cH2AX DNA damage foci did not
decrease which indicates that the effect of Torin1 on
senescent cells is not merely a result of reduced DNA
damage (Fig. 1c).
It is important to note that the Torin1 treatment was
performed in NOD Scid Gamma (NSG) mice that lack
mature T cells, B cells and natural killer cells and are
deficient in innate immunity and in multiple cytokine
pathways. These mice accumulate senescent hepato-
cytes much faster than wild-type mice. We have
shown previously that dietary restriction (60% of
ad libitum food intake) for 3 months reduced senes-
cent cell frequency in livers of wild-type mice below
starting values (Ogrodnik et al. 2017), while senescent
hepatocyte frequency remained constant in NGS mice
(da Silva et al. 2019). It is possible that mTORC1-
Fig. 1 Mice treated with Torin1 show reduced markers of
senescence. a Diagram depicting the Torin1 treatment protocol.
b, c Mouse liver samples were analysed for markers of DNA
damage (cH2AX) and senescence-associated telomere-associ-
ated DNA damage foci (see co-localisation of telo-FISH probe
and cH2AX)
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suppressing interventions like dietary restriction or
Torin1 simply diminish the senescent phenotype
without ablating the cells itself, and this is what many
have seen in vitro (Correia-Melo et al. 2016; Demi-
denko et al. 2009). However, the reduction in senes-
cent cell frequency by dietary restriction in wild-type
mice was still evident at least 3 months after return to
ad libitum feeding (Ogrodnik et al. 2017). Moreover,
in vitro, the combination of starvation and mTORC1
inhibition acted synergistically to eliminate senescent
cells (Carroll et al. 2017). Thus, it is possible that the
reduction in senescent markers shown in Fig. 1 was
due to senescent hepatocyte elimination caused by cell
death rather than resulting from phenotypic suppres-
sion or reduced induction/accumulation. While these
findings are preliminary and require robust validation
with additional senescence markers, they support our
in vitro findings and considering that inhibition of
mTORC1 in vivo is well tolerated, it warrants further
investigation and could represent a potentially pow-
erful intervention. While it is an exciting prospect that
we could one day identify simple interventions to
promote longer, healthy human lifespan, future studies
will have to investigate the repercussions of inducing
senescent cell death on tissue integrity, particularly in
tissues with low regeneration capacity. Furthermore,
understanding the mechanisms via which cell death
occurs (i.e. apoptosis, autophagy, necrosis) will be an
important consideration due to the potential damage
that excessive inflammatory and toxic factors could
cause to neighbouring tissue.
These are still early days in our quest to find
senolytic agents but mTORC1 may provide an ideal
target. Not only has its inhibition via multiple
interventions including rapamycin and calorie restric-
tion been reproducibly shown to slow the ageing
process in a wide range of model organisms including
yeast, worms, flies and many mouse models (Weich-
hart 2018), but our new data indicate that mechanis-
tically this could at least in part be due to its senolytic
activity.
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